Kacip Fatimah and the Oestrogen Receptor: Agonist, Antagonist, or Both?

Every claim made for kacip fatimah — menopause relief, bone protection, vaginal and sexual effects, and the pregnancy caution on the flip side — assumes an answer to one underlying question: does this plant act like oestrogen, block oestrogen, or something more complicated than either? Three separate laboratory literatures have now looked at this question in three different tissues, and they point in three different directions. This page lays out all three honestly, rather than quoting whichever one flatters the claim being made on a given page.

Table of Contents

  1. Why This Question Is the Hinge for Everything Else
  2. Evidence For: an Oestrogenic Phytochemical
  3. Evidence For, in a Different Tissue: Endometrial Cell Stimulation
  4. Evidence Against: Apoptosis via Oestrogen Receptor Inhibition
  5. Evidence That Complicates Both: the Postpartum Uterus Data
  6. How Can One Plant Point Three Ways?
  7. The Marketing Doesn't Reflect the Uncertainty
  8. Who This Uncertainty Actually Matters For
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Why This Question Is the Hinge for Everything Else

Oestrogen receptors alpha and beta are expressed at different densities across breast, bone, uterus, vaginal epithelium, and the hypothalamic-pituitary axis, and a molecule's effect at each site depends on receptor subtype ratio, local co-regulator proteins, and the compound's own binding behaviour — not on a single yes/no "is it oestrogenic" label. Whether kacip fatimah's active compounds behave as receptor agonists (oestrogen mimics), antagonists (oestrogen blockers), or tissue-selective modulators that do both depending on where they land, is not an academic detail. It determines whether the herb is a plausible help for hot flushes, a plausible risk in oestrogen-receptor-positive breast cancer, a plausible bone protectant, or some combination of all three simultaneously in the same person. Every other page on this hub defers the mechanistic detail to this one. Here it is, in full, with nothing smoothed over.

Back to Table of Contents

Evidence For: an Oestrogenic Phytochemical

In 2019, a Malaysian-Japanese research collaboration isolated an oestrogenic phytochemical directly from Labisia pumila and characterised its binding selectivity between the two oestrogen receptor subtypes, alpha and beta, publishing in Fitoterapia. This is a foundational, primary-source finding: it identifies an actual molecule in the plant capable of engaging oestrogen receptors, rather than inferring oestrogenicity from a downstream physiological effect. It is the closest thing the literature has to naming the compound responsible for whatever hormonal activity kacip fatimah has — and notably, the compound has not been adopted as the standardisation marker for commercial extracts, which are instead standardised to gallic acid, a compound chosen because it is easy to measure by HPLC, not because it is known to be the active one.

Back to Table of Contents

Evidence For, in a Different Tissue: Endometrial Cell Stimulation

A 2021 review in BioMed Research International, focused on kacip fatimah's effects on female reproductive disease, reports that an ethanolic extract of Labisia pumila exhibits significant estrogenic effects on a human endometrial adenocarcinoma cell line in oestrogen-free basal medium, including an increase in alkaline phosphatase secretion — a standard marker of oestrogenic stimulation in this kind of assay — and states that the water extract has been reported to displace oestrogen from antibody binding and increase estradiol production. This is worth naming precisely because unopposed stimulation of endometrial tissue is not a neutral finding: it is the same category of mechanism by which unopposed oestrogen (oestrogen without a counterbalancing progestogen) raises the risk of endometrial hyperplasia and, over time, endometrial cancer in conventional hormone therapy. The review reports this as a summary of underlying work rather than as primary data this page can independently verify further, and it is presented here at that level of confidence — but it is a second, independent tissue context in which the "oestrogenic" side of the ledger has a real entry, and it reinforces rather than undercuts the caution against use in anyone with a personal history of endometrial disease.

Back to Table of Contents

Evidence Against: Apoptosis via Oestrogen Receptor Inhibition

Set against both of the above is a 2025 study in the International Journal of Molecular Sciences, from a different Malaysian research group, working in MCF-7 cells — the standard human breast cancer cell line whose growth is specifically driven by oestrogen receptor signalling, making it one of the cleanest available models for distinguishing agonist from antagonist activity. The study found that a Labisia pumila var. alata extract produced a dose- and time-dependent antiproliferative effect on these cells, and — critically for interpretation — that this effect was blocked by fulvestrant, a drug that works specifically by degrading the oestrogen receptor. If the extract's effect disappears when the oestrogen receptor is pharmacologically removed, the effect is being mediated through that receptor. Flow cytometry showed the mechanism was apoptosis (programmed cell death), with activation of caspase 3, caspase 8 and caspase 9 — markers of both the intrinsic and extrinsic apoptotic pathways operating together. Docking analysis in the same paper confirmed the plant's phytoestrogens can physically bind both ERα and ERβ.

Read carefully, this is not simply "kacip fatimah is anti-oestrogenic." It is a receptor-mediated, pro-apoptotic effect in one specific, oestrogen-receptor-driven cancer cell line — a genuinely different, and in this specific context therapeutically interesting, result from either of the two findings above. The paper's own authors frame it as a potential lead for future breast cancer drug development, not as a general statement about the plant's hormonal direction in a healthy person's body.

Back to Table of Contents

Evidence That Complicates Both: the Postpartum Uterus Data

A third, independent dataset adds a wrinkle to both of the pictures above rather than resolving between them. The 2019 postpartum rat study examined in detail on this hub's pregnancy and postpartum safety page measured both oestrogen receptor expression and circulating hormone levels in the same animals. The result does not fit a simple "the plant raises oestrogen activity" story: expression of both ERα and ERβ in the uterus increased with rising doses of the extract, while serum estradiol actually fell at the two higher doses tested, and progesterone stayed low throughout. Receptor expression going up while the receptor's natural ligand goes down is not what a simple oestrogen mimic would produce. It is more consistent with the extract altering receptor sensitivity or density directly, independent of circulating hormone levels — a genuinely different kind of action from either straightforward agonism or straightforward antagonism, in a third tissue context from the two above.

Back to Table of Contents

How Can One Plant Point Three Ways?

These three findings are not necessarily contradictory in the sense of one being right and the others wrong. Selective oestrogen receptor modulation — a compound acting as an agonist in one tissue and an antagonist in another, depending on receptor subtype ratio and the cofactor proteins present locally — is well established pharmacology, not a special pleading invented to rescue this herb. Tamoxifen, a prescription drug, is the textbook case: it blocks oestrogen receptor activity in breast tissue (which is why it treats and prevents oestrogen-receptor-positive breast cancer) while acting like oestrogen in bone (protective) and in the endometrium (a real, monitored increased risk of endometrial cancer with long-term use). A broader pharmacology literature on isoflavones — the phytoestrogen class best studied for exactly this kind of tissue-dependent duality — documents comparable complexity: cell-type-dependent bioavailability, receptor-subtype selectivity, and effects on breast tissue that shift with dose, timing and the surrounding hormonal environment. None of this proves kacip fatimah's three findings resolve into one coherent tissue-selective profile the way tamoxifen's does; that would require dedicated head-to-head work this plant has not received. It does mean "the studies disagree, so the plant probably doesn't do much of anything" is the wrong conclusion to draw. A plant extract containing several distinct active molecules, tested in three different tissue contexts by three different groups, producing three different directional results, is exactly the pattern a genuinely tissue-selective, multi-compound modulator would produce. It is also exactly the pattern that makes "is it safe" impossible to answer with a single word.

Back to Table of Contents

The Marketing Doesn't Reflect the Uncertainty

It is worth naming a plain inconsistency in how kacip fatimah is sold. Retail and commercial health copy for the herb almost universally describes it in one register: a "phytoestrogen" that supports "hormone balance," implicitly reassuring and implicitly gentle. That framing has room for the first finding on this page and none at all for the second or third — an apoptotic, receptor-blocking effect in breast cancer cells, and a receptor-expression change decoupled from circulating hormone, are not what "supports hormone balance" prepares a buyer to expect, in either the concerning or the potentially therapeutic direction. A genuinely unresolved, tissue-dependent pharmacology is being sold as a uniformly reassuring single claim. That is not a reason to assume the worst about the herb. It is a reason not to take marketing copy's confidence as a substitute for the actual, mixed state of the evidence laid out above.

Back to Table of Contents

Who This Uncertainty Actually Matters For

Given genuine, unresolved, tissue-dependent hormonal activity, the people for whom the direction of the effect is not an academic question — and who should not be the ones finding out by trial and error — are: anyone with current or past oestrogen-receptor-positive breast cancer; anyone taking tamoxifen or an aromatase inhibitor; anyone with endometriosis, uterine fibroids, or a personal or strong family history of endometrial or ovarian cancer, given the endometrial stimulation reported above; anyone on hormone replacement therapy or oral contraceptives, where an unpredictable additive or opposing effect cannot currently be ruled either way; and, as covered in full on the pregnancy and postpartum safety page, anyone who is pregnant or breastfeeding. For everyone else, the honest summary is that the direction and magnitude of kacip fatimah's hormonal effect in a living human body remains unknown, and the herb's use should be calibrated to that uncertainty rather than to the confidence of a bottle's label copy.

Back to Table of Contents

Key Research Papers

  1. Muhamad M, Choo CY, Hasuda T, Hitotsuyanagi Y (2019). Estrogenic phytochemical from Labisia pumila (Myrsinaceae) with selectivity towards estrogen receptor alpha and beta subtypes. Fitoterapia. — PubMed
  2. Zulkifli MF, Eshak Z, Mokhtar MH, Ismail WIW (2025). Labisia pumila var. alata extract induces apoptosis cell death by inhibiting the activity of oestrogen receptors in MCF-7 breast cancer cells. International Journal of Molecular Sciences. — PubMed
  3. Zakaria AA, Noor MHM, Ahmad H, Hassim HA, Mazlan M, Latip MQA (2021). A review on therapeutic effects of Labisia pumila on female reproductive diseases. BioMed Research International. — PubMed
  4. Wan Omar WFN, Giribabu N, Karim K, Salleh N (2019). Marantodes pumilum (Blume) Kuntze (Kacip Fatimah) stimulates uterine contraction in rats in post-partum period. Journal of Ethnopharmacology. — PubMed
  5. Exploring the complex mechanisms of isoflavones: from cell bioavailability, to cell dynamics and breast cancer (2025). Phytotherapy Research. — PubMed
  6. Estradiol and estrogen-like alternative therapies in use: the importance of the selective and non-classical actions (2022). Biomedicines. — PubMed
  7. Shuid AN, Ping LL, Muhammad N, Mohamed N, Soelaiman IN (2011). The effects of Labisia pumila var. alata on bone markers and bone calcium in a rat model of post-menopausal osteoporosis. Journal of Ethnopharmacology. — PubMed
  8. Nadia ME, Nazrun AS, Norazlina M, et al. (2012). The anti-inflammatory, phytoestrogenic, and antioxidative role of Labisia pumila in prevention of postmenopausal osteoporosis. Advances in Pharmacological Sciences. — PubMed
  9. Norhayati MN, George A, Hazlina NH, et al. (2014). Efficacy and safety of Labisia pumila var alata water extract among pre- and postmenopausal women. Journal of Medicinal Food. — PubMed
  10. Wang Y, Yan F, Xu DQ, et al. (2025). Traditional uses, botany, phytochemistry, pharmacology and applications of Labisia pumila: a comprehensive review. Journal of Ethnopharmacology. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents